Podcasts about medical update

Opening on the Grizzlies' Medical Update on Ja Morant & KCP: Will Ja Return This Season or Is He Officially Out? Jaren Jackson Jr.'s Farewell Message to Memphis.

Doctors explain stress-induced cardiomyopathy, symptoms, and who is most at risk.

Schicket bitte Fenti odr Heroingüetzeni, merci.

Steve Deace. It's the END of the Republic (Without Arrests) and MAHA Legal-Medical Update. Steve Deace Show https://podcastaddict.com/steve-deace-show/episode/215425394  Jan 21 2026   Steve says if the DOJ isn't serious about making arrests and real prosecutions against some of the worst actors on the political scene, the republic is likely toast. Then, Brian Festa from We the Patriots USA provides an update on MAHA in the legal-medical realm, what cases he's currently pursuing, and a terrifying medical kidnapping story

We got an update on all the guys who have been suffering from medical issues and it includes a new pain in a sensitive region for Lunchbox. Bobby talked about the tragic headlines from over the weekend including the shooting at Brown University and the passing of Robert Reiner. In the Anonymous Inbox, Bobby gives his thoughts on a listener who's fiancé wants his female best friend to be his 'best woman' in their wedding. She wants to know if she is justified in the idea of it making her uncomfortable.See omnystudio.com/listener for privacy information.

We got an update on all the guys who have been suffering from medical issues and it includes a new pain in a sensitive region for Lunchbox. Bobby talked about the tragic headlines from over the weekend including the shooting at Brown University and the passing of Robert Reiner. In the Anonymous Inbox, Bobby gives his thoughts on a listener who's fiancé wants his female best friend to be his 'best woman' in their wedding. She wants to know if she is justified in the idea of it making her uncomfortable.See omnystudio.com/listener for privacy information.See omnystudio.com/listener for privacy information.

The holidays can mean parties, binge drinking and rushing around. It can be exhausting. It can also be hard on your heart. We discuss "holiday heart." Our team of doctors also shows you how easy it is to get a clear baseline with a simple cardiac test.

Two sisters share more than just family bond- they also share a breast cancer diagnosis. We take a look at genetics and breast cancer.

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this Friday Headline Brief of The Wright Report, Bryan covers the planned “No Kings” protests across the U.S., Antifa-linked terrorism charges, IRS whistleblower Gary Shapley's new probe into leftist funding networks, major indictments involving voting machine companies, the arrest of former National Security Advisor John Bolton, and a surprising Pentagon media shake-up.   Nationwide “No Kings” Protests: Over 200 leftist groups — including Indivisible and the Communist Party USA — are coordinating mass demonstrations against President Trump. Organizers admit they're modeling the effort on past “color revolutions,” with foreign influence on Reddit shaping messaging and funding. Paid agitators and billionaire donors like George Soros and Christy Walton are also backing the events.   Antifa Terrorism Charges in Texas: Two Antifa members were indicted for a July 4th attack on an ICE facility that left a police officer shot in the neck. Bryan warns the group will likely appear at this weekend's protests.   IRS Whistleblower Targets Leftist Donors: Gary Shapley, who helped expose Hunter Biden's tax scandal, is now working with the Trump administration to investigate non-profits and mega-donors funding extremist groups. Democrats call it “revenge,” while Trump's team insists “no one is above the law.”   Voting Machine Scandals: Smartmatic was indicted for bribing foreign officials to win contracts abroad, while Dominion was sold and rebranded as “Liberty Vote.” Bryan calls for a return to secure, paper-based elections, drawing on his CIA experience hacking offline systems.   John Bolton Indicted for Leaking Secrets: Bolton faces 18 felony counts for retaining and transmitting classified CIA materials through personal email. Iranian hackers accessed his devices, endangering American operatives. Bryan says, “He traded lives for a book deal.”   Pentagon Restricts Media Access: Journalists walked out after new rules allowed revoking press credentials for soliciting classified info. Bryan calls it “a long-overdue correction” given partisan infiltration of the press.   China, Asia, and the Americas: Trump eyes aid to the Solomon Islands to counter China, supports Japan's conservative coalition, mediates peace between Thailand and Cambodia, and monitors troop mobilization in Venezuela.   Medical Breakthrough — Gut Health and Cancer: University of Pennsylvania researchers found that exercise boosts gut bacteria producing formate, improving cancer immunotherapy. Fermented foods like yogurt, kimchi, and kefir may help patients recover faster.   "And you shall know the truth, and the truth shall make you free." - John 8:32     Keywords: No Kings protest Indivisible color revolution, Antifa ICE attack Texas, Gary Shapley IRS Soros probe, Smartmatic bribery indictment, Dominion Liberty Vote sale, John Bolton indictment Top Secret leaks, Pentagon media rules transparency, Thailand Cambodia peace talks Trump, Venezuela drone strike, University of Pennsylvania gut bacteria cancer study

Skin cancer can be aggressive, and it doesn't always stay on the surface. Hear one woman's powerful story of choosing surgery and immunotherapy to fight back.

With all the changes going on in the CDC, Dr. Sydnee and Justin check back in with an update on vaccines and vaccine mandates, as well as dispelling some common vaccine myths that unfortunately come up again and again.Music: "Medicines" by The Taxpayers https://taxpayers.bandcamp.com/Equality Florida: https://www.eqfl.org/

From professional athletes and cheering fans to high school players and coaches on the sidelines — they all share one critical need: a well-prepared emergency action plan. When seconds matter, preparation saves lives. We'll show you real-world examples where quick action made all the difference.

Could McAtee be the second signing this week? Forest will have to increase their bid first! For Exclusive Content Join FFTV Patreon: https://www.patreon.com/ForestFanTV Welcome to Forest Fan TV for the latest transfer update on Nottingham Forest! Breaking news today reveals that Manchester City have rejected a £25m bid for their midfielder James McAtee, with the Premier League giants holding out for a higher fee despite the player entering the final year of his contract. Forest, eager to bolster Nuno Espirito Santo's squad after losing Anthony Elanga, see McAtee as a key target, but City's valuation—closer to £35m or more—has sparked debate. Should Forest return with a bigger offer for a player whose game time could be limited under Pep Guardiola, or is this a risky move with his contract winding down? We also have an update on the exciting new signing, Dan Ndoye, who is currently undergoing his medical after Forest secured the Bologna winger in a €40m deal, as confirmed by Fabrizio Romano earlier today. The Swiss international is set to add pace and flair to the Reds' attack, and fans are buzzing about his imminent arrival at the City Ground. With personal terms agreed and no release clause in his new contract, this looks like a solid long-term investment—though the medical outcome remains a key focus as we await official confirmation. Could the deal for Lyon's Malick Fofana be back on the table? Recent reports suggest Forest are rekindling interest in the young forward, who was previously targeted earlier this window. With Ndoye nearing completion and McAtee's future uncertain, could Fofana provide additional depth? Jump into the comments and share your thoughts on whether Forest should up their bid for McAtee, your excitement for Ndoye, or your take on the Fofana rumours. Don't forget to like, subscribe, and hit the bell for more updates! #nffc #mancity #transfernews Learn more about your ad choices. Visit podcastchoices.com/adchoices

I hit 3.7 million Subscribers on YouTube!! To celebrate, I asked for questions from YouTube, X, and Instagram, so here's another 90 minutes of me trying to answer as many as possible. Expect to learn all about my new hairstyle, how to best deal with procrastination, which people are up next on my "Mount Rushmore" of podcast guests, what the current state of my health is, the best tips to manage stress, when podcast merch will be coming to a closet near you, which future music guests I want on the pod, the real power of money, and much more... Sponsors: See me on tour in America: ⁠https://chriswilliamson.live⁠ See discounts for all the products I use and recommend: https://chriswillx.com/deals Get 35% off your first subscription on the best supplements from Momentous at https://livemomentous.com/modernwisdom Get 10% discount on all Gymshark's products at https://gym.sh/modernwisdom (use code MODERNWISDOM10) Get the brand new Whoop 5.0 at https://join.whoop.com/modernwisdom Timestamps: (0:00) - Go See Chris Live (1:19) - What's Up with the Curly Hair? (3:28) - How To Deal with Procrastination (5:39) - Chris' Go-To Shorts (6:58) - Future Musical Guests (8:09) - Why Won't She Commit? (11:42) - Who's in the Next ‘Infinity Gauntlet'? (13:34) - Will James Sexton and Sadia Khan Be Back? (13:56) - The Impact of the Male Sedation Hypothesis on Masculinity (18:15) - Chris' Medical Updates (23:53) - The Negative Effects of Reality Shows (28:47) - How Money Can Change Your Life (32:49) - Top Tips on Stress Management (36:36) - Where Will We Be in 10 Years? (42:30) - Is Chris a Deano? (44:04) - Cool Kids Names (45:05) - How to Get Over Ghosting (49:17) - Modern Wisdom Merch (50:20) - A Love Life Catch-22 (56:58) - Dating in Your 30s (01:00:24) - How the Modern Wisdom Team was Built (01:02:19) - Are 20-Year-Olds Still Partying? (01:04:39) - The Art of Drifting (01:05:50) - How to Tackle Regret (01:07:53) - Reading List (01:09:38) - Being Loved for Being Your Authentic Self (01:14:37) - The Benefits of Having Siblings (01:16:07) - Thoughts on Travelling Alone (01:17:06) - The Rise of Hybrid Athletes (01:18:26) - Don't Ruin Your Phone with a Phonecase (01:19:15) - Comfort Over Style (01:21:35) - Settling Down (01:24:28) - Being Roasted by Fin Taylor (01:25:20) - Seeing Sleep Token (01:25:49) - Tips on Tinnitus (01:27:18) - Would Chris Beat Lex Fridman? (01:27:28) - Outro Extra Stuff: Get my free reading list of 100 books to read before you die: https://chriswillx.com/books Try my productivity energy drink Neutonic: https://neutonic.com/modernwisdom Episodes You Might Enjoy: #577 - David Goggins - This Is How To Master Your Life: https://tinyurl.com/43hv6y59 #712 - Dr Jordan Peterson - How To Destroy Your Negative Beliefs: https://tinyurl.com/2rtz7avf #700 - Dr Andrew Huberman - The Secret Tools To Hack Your Brain: https://tinyurl.com/3ccn5vkp - Get In Touch: Instagram: https://www.instagram.com/chriswillx Twitter: https://www.twitter.com/chriswillx YouTube: https://www.youtube.com/modernwisdompodcast Email: https://chriswillx.com/contact - Learn more about your ad choices. Visit megaphone.fm/adchoices

Ken Carman and Anthony Lima take you through what you may have missed 'About Last Night'!

Medical experts discuss federal vaccine orders, and answer questions about Covid, measles, tick-borne diseases and other seasonal health concerns

Ginny Curtin is living with sarcoma. She's not just surviving- she's thriving and sharing her perspective with fellow patients. This includes amazing adventures packed with incredible photography.

Good health means good sleep. We ask what's keeping us from a restful night in bed? Learn from the expert.

A young mom discovers a lump and learns she has triple negative breast cancer. She shares her journey and the supports she found from family, friends and faith.

She spotted her own ovarian cancer. Now she's keeping it in check. Hear one woman's story regarding her diagnosis and survivorship.

Medical Update and Major Announcement. Monday's Travel and Cruise Industry Podcast; February 24, 2025, brought to you by Whill_US, owner of Scootaround and Chillies Cruises. #fMondaytravelandcruiseindustrypodcast #travelandcruiseindustrynews #podcast #cruisenews #travelnews #cruise #travel #chilliescruises #chilliefalls #whill_us Thanks for visiting my channel. NYTimes The Daily, the flagship NYT podcast with a massive audience. "Vacationing In The Time Of Covid" https://nyti.ms/3QuRwOS To access the Travel and Cruise Industry News Podcast; https://cms.megaphone.fm/channel/trav... or go to https://accessadventure.net/ To subscribe: http://bit.ly/chi-fal I appreciate super chats or any other donation to support my channel. For your convenience, please visit: https://paypal.me/chillie9264?locale.... Chillie's Cruise Schedule: https://www.accessadventure.net/chillies-trip-calendar/ For your mobility needs, contact me, Whill.inc/US, at (844) 699-4455 use SRN 11137 or call Scootaround at 1.888.441.7575. Use SRN 11137. YouTube: https://www.youtube.com/ChilliesCruises Facebook: https://www.facebook.com/chillie.falls X: https://x.com/ChillieFalls Learn more about your ad choices. Visit megaphone.fm/adchoices

Today on show: A frontline medical update on the Gaza genocide, as Trump continues to advocate for the complete ethnic cleansing of Gaza. Also, Poet Anita barrows returns as she continues to keep track of the Gaza slaughter poem by poem, and day after murderous day. Today she documents the 23rd day of the ceasefire. We'll feature A commentary by Caitlan johnstone, “The Gaza Ceasefire Is Being Sabotaged By Israel, By Trump, and The Media:”.  And Gavin Newsom turns his back on solar energy The post A Frontline Medical Update on The Genocide in Gaza appeared first on KPFA.

Health care leaders answer questions about rising cases of flu and Covid-19, as well as other public health concerns

The Fat One closes out the first FULL week of 2025 with an update on Garry with 2 Rs, gentlemen callers, Ubering Vader to the aeropuerto (which we all know is Mexican for, Aeropuerto), a trip to the Sam's Club and the Wednesday coupon. Happy National Bittersweet Chocolate Day.

It's always great to connect with old friends. In this case, the positive power of social media helped a breast cancer patient find specialized care.

Treating breast cancer isn't just about the disease--it's about the whole person. Meet the cosmetologists helping women regain their confidence.

Severe food allergies can make each meal a challenge– and expensive. Meet a mom whose own fight to feed her daughters has led to better access for Medicaid patients everywhere. Visit our website, www.kansashealthsystem.com or findadoctor.kansashealthsystem.com.

After last week's electrocution incident, I update the Glade Plugins medical department on my recent doctor's visit and receive some startling disinformation vis-à-vis which of their products is safe to heat up on the stove.

Hey there, buttercup! In this episode Chalene dives into the ongoing medical mystery—spoiler alert, it's still a mystery! She stresses again hormone replacement therapy and why it's essential for women over 40. Plus, get Chalene's thoughts on a Netflix docu-series about the Dallas Cowboys Cheerleaders that serves up a shocking dose of '90s-style body shaming. Tune in for all the juicy details and more!  Join the all-new Phase It!! A Personalized Plan to Fit Your Life

Human excrement used as a treatment?! Meet someone who needed a fecal microbiota transplant to reset her gut's microbiome.

Summer heat comes with health concerns, and it doesn't even need to be sweltering hot before your body reacts. From the danger of hot cars to the medications that put us at higher risk of heat illness. Today we're focused on giving you valuable information to keep you and your loved ones safe this summer.

Seeing a doctor doesn't mean you're weak. Seeking help has nothing to do with masculinity. Join us for an important discussion aimed at ending the stigma surrounding men's health.

Skin cancer is rarely "one-and-done". Patient Kevin Shea needed surgery, more than a decade after his original diagnosis! Surviving melanoma, how doctors keep tabs on where the cancer may spread.

Gestational diabetes, a condition that often has no symptoms, catching pregnant women by surprise, and putting their babies at risk. We look at the danger for both mother and baby. Plus, how experts teach expecting moms to protect their metabolic health.

It's tough to talk about Alzheimer's, but we shouldn't shy away from such important conversations. We hear from a caregiver, and get and update on the newest Alzheimer's drugs.

4 years into the COVID Pandemic and this shared traumatic experience has changed us. The deaths, the division and the uncertainty are still taking a toll mental health. Experts call it a collective trauma facing society.

Countless creams, gels and drugs promise to reverse the effects of menopause. Now doctors have a laser in their toolbox the five-minute treatment promising less dryness and pain.

Waiting for a new kidney sapped Amy Reinhardt's energy, but it never shook the 27-year-old's faith. How Amy connected to a community of patients just like her and learned to endure life on the transplant list.

Answers to your questions about Covid, vaccines, flu and other health matters

A party for a princess- 3-year-old Olivia is hoping to put cancer treatment behind her. The rare tumor that first showed up as a gut infection. And the urgent treatment giving her the best shot at a bright future.

A brother and sister's bond is amplified when he donates his bone marrow to save her life. Watch all episode - Morning Medical Update Cancer: Choices, Hope and Science   

in today's episode I give an update on what is going on with me and hopefully motivate some of my listeners to LISTEN to the signs your body is giving you. I break down overtraining syndrome and the different phases. If you have struggled with overtraining or you are struggling with living the high stress lifestyle that mimics it, I would love to have you on board in my road to recovery. If you have recovered from overtraining syndrome, I would love to hear your experience and how you managed to overcome it.Shoot me a message: IG @cherylnassoFB @cherylnassoEMAIL cheryl@myfitbodyrx.com Schedule a free nutrition strategy call below:https://formfaca.de/sm/8F3alRLhKJoin My Free Facebook Group: LIVE TRAININGS, SUPPORT, EDUCATION :https://www.facebook.com/groups/141933950164494

In this Medical Update, Buck talks about one quick thing you can do to significantly improve the quality of your sleep. It goes against what we've been told but everyone should do it. The data backs it!

Sponsored by www.betterhelp.com/TheBarnVulgar Display of Podcast: Instagram | Twitter | FacebookBetterHelp, Zymurgy Brewing, Black Bayou Coffee Roasters, Michael Haley Photography, Total Deathcore, Liquid DeathMoontooth is a name that resonates with the raw, unbridled energy of heavy rock. Hailing from New York City, this quartet has been forging a unique path in the world of modern rock music, offering a blend of hard-hitting riffs, intricate melodies, and emotive lyrics that captivate audiences and challenge genre boundaries.Formed in 2012, Moontooth consists of John Carbone (vocals/guitar), Nick Lee (lead guitar), Vincent Romanelli (bass), and Ray Marte (drums). From their early beginnings, they showcased a fearless approach to their music, combining elements of hard rock, metal, and progressive rock into a sound that defies easy categorization.One of Moontooth's defining features is their powerful and dynamic live performances. They bring an intensity to the stage that electrifies audiences, leaving them in awe of the band's musicianship and sheer sonic force. Whether they're headlining a show or supporting larger acts, Moontooth's stage presence is undeniable, and their performances are memorable experiences.In 2014, they released their self-titled EP, which served as a promising introduction to their sound. However, it was their 2016 full-length debut album, "Chromaparagon," that truly put them on the map. The album received critical acclaim and showcased the band's ability to craft songs that were simultaneously heavy and melodic, featuring intricate guitar work and Carbone's distinctive, emotive vocals.One of the standout tracks from "Chromaparagon" is "Queen Wolf," which exemplifies Moontooth's ability to create music that blurs the line between hard rock and progressive metal. The song's heavy riffing, time signature changes, and evocative lyrics are a testament to the band's songwriting prowess.Moontooth's evolution as a band continued with their 2019 release, "Violent Grief: Acoustic Selections." This EP demonstrated their versatility by presenting stripped-down, acoustic versions of their songs. It was a departure from their heavier sound but showcased their songwriting depth and Carbone's emotive vocals.In a music landscape where genres are constantly evolving, Moontooth stands as a beacon of innovation and fearless creativity. Their ability to merge heavy rock with intricate compositions and genuine emotion sets them apart and ensures their place in the future of modern rock. Whether on record or onstage, Moontooth continues to shape the future of heavy rock, and fans eagerly anticipate what they will deliver next.This episode is sponsored by www.betterhelp.com/TheBarn and presented to you by The Barn Media Group.

Hour 1: Tiki and Tommy talk about the Mets big win in Atlanta last night and if Mets fans should be buying into the recent success of the team. They also provide an update on Evan's sickness with an official word on his ailment(s). 

What about oral?? Lewis GD et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: The IRONOUT HF randomized clinical trial. JAMA 2017 May 16; 317:1958. (http://dx.doi.org/10.1001/jama.2017.5427. opens in new tab) randomized, 225 patients with symptomatic systolic HF for 16-weeks to either  oral iron polysaccharide 150 mg twice daily and placebo in 225 patients with symptomatic systolic HF (median left ventricular ejection fraction, 25%) At 16 weeks, the groups did not differ on the primary endpoint of peak oxygen consumption (VO2) or on secondary endpoints, including 6-minute walk distance and quality of life as measured with the Kansas City Cardiomyopathy Questionnaire. Thus as you mentioned not only is it not well tolerated it also doesn't appear to work which might be a better reason to not give it.https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0279166Vitamin D2 supplementation was associated with a 48.8% reduction in suicide/self-harm risks, and vitamin D3 with a 44.8% reduction, both highly significant (P < .001).   this sounds great but it is purely relative reduction not absolute because the absolute numbers wereUnadjusted suicide attempt/intentional self-harm rates in the D2 sample were 0.27% for those treated versus 0.52% for those untreated. The corresponding percentages for D3 were 0.20% versus 0.36%, respectively.Which equals a NNT of roughly 400 and 625 over 8 yrs, respectfully.IF this was true then that actually isn't too bad (not good or great but not terrible) but this was a retrospective observational trial so they just looked at a lot of people and said what can we find and publish.So what are other reasons that someone would not commit suicide??My first thought is ‘you only get put on vit d if you go to the doctor” (which is true)And typically the people that go to the doctor for their health care a little more about their health than someone who commits suicideClearly this isn't a universal answer but possibleAnother thought isthe vet that goes to the doctor and gets prescribed vit d feels like someone “cares for him/her” so maybe it has nothing to do with the vit d but just the sense of reassurance that someone cares about them?? Based on this I still wouldn't/wont write for vitamin d unless you need cheap placebo since we cant actually write for placeboD'Andrea E et al. Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels. JAMA Intern Med 2023 Feb 6; [e-pub]. Sodium–glucose cotransporter-2 (SGLT-2) inhibitors are used to manage type 2 diabetes but also have protective cardiovascular and renal effects.  Do these benefits and adverse effects vary according to baseline level of hyperglycemia SGLT-2 inhibitors were compared with propensity-score–matched patients who initiated dipeptidyl peptidase-4 (DPP-4) inhibitors, within three categories of HbA1c: 9%. After mean follow-up of 8 months, initiation of SGLT-2 inhibitors was associated with significantly lower risks for major adverse cardiovascular events and hospitalization for heart failure, DUH we know this works in people that don't have diabetes why is it a surprise that it works in those with uncontrolled or controlled diabetes. To me this points to the problem that A1C is a number, it is not the problem, a bad A1C says there could be a problem in the future but in itself the A1C is a number!Buelt, Andrew | Apr 19, 2023, 3:25 PM | | to meTreat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial | Cardiology | JAMA | JAMA Network JAMA. 2023;329(13):1078-1087. doi:10.1001/jama.2023.2487  randomized noninferiority trial 4400 patients Question  Is treatment to a goal low-density lipoprotein cholesterol (LDL-C) level between 50 and 70 mg/dL noninferior to a strategy using high-intensity statin therapy among patients with coronary artery disease? To assess whether a treat-to-target strategy is noninferior to a strategy of high-intensity statins for long-term clinical outcomes in patients with coronary artery disease.Patients were randomly assigned to receive either the LDL-C target strategy, with an LDL-C level between 50 and 70 mg/dL as the target, or high-intensity statin treatment, which consisted of rosuvastatin, 20 mg, or atorvastatin, 40 mg.  Which isn't HIGH in my book that that is fine.  Primary end point was a 3-year composite of death, myocardial infarction, stroke, or coronary revascularization with a noninferiority margin of 3.0 percentage points. The primary end point occurred in (8.1%) in the treat-to-target group and (8.7%) in the high-intensity statin group  Worst conclusion ever“Conclusions and Relevance  Among patients with coronary artery disease, a treat-to-target LDL-C strategy of 50 to 70 mg/dL as the goal was noninferior to a high-intensity statin therapy for the 3-year composite of death, myocardial infarction, stroke, or coronary revascularization. These findings provide additional evidence supporting the suitability of a treat-to-target strategy that may allow a tailored approach with consideration for individual variability in drug response to statin therapy.” Let's see if something that's much more difficult and costly and more blood draws and more work and more office appointments is non inferior to something that's easier such as take this medication and that it………………………………... Then why it is, we recommend the much more difficult thing.     Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial | Cardiology | JAMA | JAMA Network JAMA. 2023;329(13):1078-1087. doi:10.1001/jama.2023.2487  randomized noninferiority trial 4400 patients Question  Is treatment to a goal low-density lipoprotein cholesterol (LDL-C) level between 50 and 70 mg/dL noninferior to a strategy using high-intensity statin therapy among patients with coronary artery disease? To assess whether a treat-to-target strategy is noninferior to a strategy of high-intensity statins for long-term clinical outcomes in patients with coronary artery disease.Patients were randomly assigned to receive either the LDL-C target strategy, with an LDL-C level between 50 and 70 mg/dL as the target, or high-intensity statin treatment, which consisted of rosuvastatin, 20 mg, or atorvastatin, 40 mg.  Which isn't HIGH in my book that that is fine.  Primary end point was a 3-year composite of death, myocardial infarction, stroke, or coronary revascularization with a noninferiority margin of 3.0 percentage points. The primary end point occurred in (8.1%) in the treat-to-target group and (8.7%) in the high-intensity statin group  Worst conclusion ever“Conclusions and Relevance  Among patients with coronary artery disease, a treat-to-target LDL-C strategy of 50 to 70 mg/dL as the goal was noninferior to a high-intensity statin therapy for the 3-year composite of death, myocardial infarction, stroke, or coronary revascularization. These findings provide additional evidence supporting the suitability of a treat-to-target strategy that may allow a tailored approach with consideration for individual variability in drug response to statin therapy.” Let's see if something that's much more difficult and costly and more blood draws and more work and more office appointments is non inferior to something that's easier such as take this medication and that it………………………………... Then why it is, we recommend the much more difficult thing.        Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence | NEJMN Engl J Med 2023; 388:781-791  Thiazide diuretic agents are widely used for prevention of the recurrence of kidney stones, but data regarding the efficacy of such agents as compared with placebo are limited.  double-blind RCT  patients with recurrent calcium-containing kidney stones were randomized to hctz 12.5 mg, 25 mg, or 50 mg once daily or placebo once daily.  primary end point, a composite of symptomatic or radiologic recurrence of kidney stones. Symptomatic= The visible passage of a stone and radiologic =Appearance of new stones on CT 416 patients were randomized and followed for almost 3yrs primary end-point event occurred in (59%) in the placebo group (59%) in the 12.5-mg hydrochlorothiazide group (56%) in the 25-mg group(49%) in the 50-mg group  (rate ratio, 0.92; 95% CI, 0.63 to 1.36) No difference in any of the subgroups that was looked at there was no difference in the stone composition if it was calcium oxalate or calcium phosphate there was no difference Some women and people of race were underrepresented in this study but when you have a well done study that is the best we have the burden of proof now falls on you to prove there is benefit… for me this goes against board questions and what I thought was true and will lead me to stopping HCTZ if I am using it for prevention of kidney stones. 

Lindholt JS, Søgaard R, Rasmussen LM, et al. Five-year outcomes of the Danish cardiovascular screening (DANCAVAS) trial. N Engl J Med 2022;387(15):1385-1394.     Study design: Randomized controlled trial (nonblinded) Looking to see if intensive screening protocol for cardiovascular disease reduce cardiovascular events or mortality in older men? Danish study, 46,611 men aged 65 to 74 years were randomly assigned to receive an invitation to screening or usual careThe screening program included non-contrast electrocardiographically gated CT to measure coronary artery calcium, look for aneurysms, and detect atrial fibrillation; ankle-brachial index measurements for peripheral arterial disease (PAD) and hypertension; and blood tests for diabetes and hyperlipidemiaThose who accepted screening were more educated, more likely to be employed, and had a somewhat lower rate of hospitalization for cardiovascular events in the previous 5 years. (the rich white gullible ceo male)The screened group was more likely to be given lipid-lowering drugs and antithrombotics, and they were more likely to have repair of an aortic aneurysm.In the entire population, stroke was less likely (HR 0.93; 0.86 - 0.99) but there were no significant differences in myocardial infarction, aortic dissection, or aortic rupture. The authors estimated that 97.4% of men who received preventive therapy of some kind as a result of screening experienced no mortality benefit after almost 6 yrs of follow up. This is basically a really small absolute benefit which we could also see in just placing a pt on a statin. We don't need vip medicine we need pcp that have time to calculate risk and place pt on statin when indicated.     Goldberg RB, Orchard TJ, Crandall JP, et al, for the Diabetes Prevention Program Research Group. Effects of long-term metformin and lifestyle interventions on cardiovascular events in the diabetes prevention program and its outcome study. Circulation 2022;145(22):1632-1641. Study design: Randomized controlled trial (nonblinded) What is the long-term impact of treating prediabetes on mortality and cardiovascular outcomes? Go way back original Diabetes Prevention Program study randomized 3234 overweight or obese adults with impaired glucose tolerance ("prediabetes") to receive metformin 850 mg twice daily, an intensive exercise program, or placebo and followed them for 3 years Patients were invited to participate in a long-term open-label follow-up study This article reports long-term cardiovascular and mortality outcomes for each group. Patients in the intervention groups were less likely to have been given a diagnosis of T2DM (55% for metformin and 53% for lifestyle vs 60% for placebo; P = .001; number needed to treat [NNT] = 17) There was no difference between either intervention group and placebo with regard to the risk of cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction. There was also no significant difference in the composite of all 3 outcomes for the original metformin group versus the placebo group (hazard ratio [HR] 1.03; 95% CI 0.78 - 1.37) or for those in the original lifestyle group versus the placebo group (HR 1.14; 0.87 - 1.50). More is less or rather more meds is less diagnosis but no difference in things we actually care about     Skjerven HO, Lie A, Vettukattil R, et al. Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet 2022;399(10344):2398-2411. Study design: Randomized controlled trial (single-blinded) Does the early introduction of allergenic foods prevent the development of food allergy? investigators randomized healthy newborns, singletons or twins, with at least 35 weeks' gestational age (concealed allocation) to receive no intervention (n = 597), a skin intervention (n = 575), a food intervention (n = 642), or a combined intervention (n = 583). The skin intervention consisted of 5- to 10-minute baths with added petrolatum-based emulsified oil followed by topical cetirizine cream applied to the face. This intervention was to occur at least 4 days per week from age 2 weeks to 8 months, The food allergy intervention consisted of sequentially adding allergenic foods (peanuts, cow's milk, wheat, then eggs) to the infants' regular diet at weekly intervals starting at age 3 months. Overall, 95% of the infants in each group were breastfed at 3 months The researchers had final data on 99.9% of the participants!   based on structured parental interviews, skin testing, and oral challenges  The researchers classified the development of food allergy at 36 months as probable, none, or unclear.  There was no significant difference, however, between the infants who were exposed to skin interventions and those who were not exposed (2.1% vs 1.6%). BUT BUT BUT Food allergy occurred in 1.1% of infants in the interventions using food (food intervention and combination intervention) compared with 2.6% in not using food (no intervention and skin intervention; number needed to treat = 63; 95% CI 37-196).   Lewis E, Merghani K, Robertson I, et al. The effectiveness of leucocyte-poor platelet-rich plasma injections on symptomatic early osteoarthritis of the knee: the PEAK randomized controlled trial. Bone Joint J 2022;104-B(6):663-671. Study design: Randomized controlled trial (double-blinded) Allocation: Concealed recruited adults with at least 4 months of knee pain (with or without swelling) who had mild degeneration on their x-rays (if plain x-rays found no signs of degeneration, they used magnetic resonance imaging to confirm the diagnosis). The participants were randomized to receive 3 weekly saline injections (n = 28), or a single PRP injection followed by 2 weekly saline injections (n = 47), or 3 weekly PRP injections (n = 27). . The clinician performing the injections was unmasked but had no other involvement in the study procedures. the participants were evaluated at 6 weeks, 12 weeks, 6 months, and 12 months after enrollment Using intention-to-treat analysis looking at pain, function, and quality of life, at no point in the study were PRP injections, singly or serially, superior to saline injections.

Efficacy and Safety of Intensive Versus Nonintensive Supplemental Insulin With a Basal-Bolus Insulin Regimen in Hospitalized Patients With Type 2 Diabetes: A Randomized Clinical Study | Diabetes Care | American Diabetes Association (diabetesjournals.org)   randomized noninferiority study from Emory University, 224 hospitalized patients with longstanding type 2 diabetes  Both groups received basal/bolus insulin; both the starting dose and subsequent changes were specified by the study protocol. Additional premeal SSI was added to scheduled premeal bolus doses.randomized to either intensive SSI (at BG >140 mg/dL) or nonintensive SSI (at BG >260 mg/dL) before meals and at bedtime.  Mean baseline glycosylated hemoglobin (HbA1c) was 9%, and 60% of patients were using insulin at home. Patients with a presenting glucose level of >400 mg/dL or diabetic ketoacidosis were excluded.  Outcome---Mean daily BG level, hypoglycemia, severe hyperglycemia, percent of BGs in the target range (70–180 mg/dL), and the amount of total, basal, or prandial insulin used did not differ between groups. However, significantly fewer patients in the nonintensive group than in the intensive group received SSI (34% vs. 91%).   COMMENTAlthough this is a single-center study, its results are persuasive and suggest that a less-intense SSI regimen can achieve similar glucose outcomes in hospitalized patients with type 2 diabetes who are receiving basal/bolus insulin. It also could decrease nursing treatment burden. As we move slowly toward more continuous glucose monitoring in hospitals, reducing use of SSI is another opportunity to achieve similar results with less staff burden and more patient comfort.  Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation: A Multinational Population-Based Cohort Study: Annals of Internal Medicine: Vol 175, No 11 (acpjournals.org) In a retrospective study, investigators accessed five electronic health databases from Europe and the U.S. to compare >500,000 new DOAC users with newly diagnosed atrial fibrillation. Follow up varied from 1.5 to 4.5 years.   In propensity score–adjusted analyses, patients who received apixaban had significantly less gastrointestinal (GI) bleeding did those who received any of the other three drugs (hazard ratios, 0.7–0.8). This result was consistent among older patients and those with chronic kidney disease (CKD). Risk for stroke or other systemic embolism, intracranial hemorrhage, and all-cause mortality did not differ significantly among DOACs.    COMMENTThis is the largest comparison of individual DOACs, and it demonstrates similar efficacy among all agents. Although apixaban was associated with less GI bleeding, absolute percentages of GI bleeds ranged from ≈2% to ≈3.5% for all DOACs; therefore, apixaban's statistically significant safety benefit might amount to marginal clinical benefit for any individual patient. I might turn to apixaban for patients at high risk for GI bleeding (and those with CKD), but all DOACs remain reasonable options for preventing thromboembolism in most patients with atrial fibrillation. Ellenbogen MI et al. Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study. J Hosp Med 2022 Oct; 17:809. (https://doi.org/10.1002/jhm.12926. opens in new tab)  . In an industry-funded retrospective study, investigators used a national database (years, 2014–2018) and propensity score–adjusted analysis to compare outcomes among >11,500 patients with ESRD and newly diagnosed VTE who received either apixaban or warfarin.Only 2% of patients received apixaban in 2014, but 47% received apixaban in 2018.during the 6 months following initiation of therapy, apixaban — compared with warfarin  associated with significantly lower incidence of major bleeding (10% vs. 14%), including intracranial bleeding (1.8% vs. 2.5%) and gastrointestinal bleeding (8.6% vs. 10.4%). Recurrent VTE and all-cause mortality were similar in the two groups.   VTE and creatine clearence less than 30 then I think apixaban is the drug of choice—I would like to see this study don't with afib and done with exclusively